HomeMCPWorkbenchSkills
HomeWorkbenchNotificationsMe
llms.txt · MCP GuidePrivacy Policy · Terms of Service · Supportv1.8.3
  1. Home
  2. /Compound

Chenodeoxycholic Acid

HCID 10133
New reaction
Print
Basic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes
Substructure searchFind similar structures

Basic information

CAS
474-25-9
Standard SMILES
C[C@H](CCC(=O)O)[C@H]1CC[C@H]2[C@@H]3[C@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C
InChIKey
RUDATBOHQWOJDD-BSWAIDMHSA-N
Molecular formula
C24H40O4
Average molar mass
392.6 g/mol
Monoisotopic mass
392.29265975

Overview

Chenodiol can cause developmental toxicity according to state or federal government labeling requirements.

Names & identifiers

Preferred name
Chenodeoxycholic Acid
IUPAC
(4R)-4-[(3R,5S,7R,8R,9S,10S,13R,14S,17R)-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoic acid
English name
Chenodeoxycholic acid
Molecular formula
C24H40O4
Molecular weight
392.57

Names & synonyms

chenodeoxycholic acidChenodiol474-25-9ChenixCdcaChenic acidChenodesoxycholic acidChendolGallodesoxycholic acidAnthropodeoxycholic acidAnthropodesoxycholic acidAnthropododesoxycholic acid
Show more names
CHENODEOXYCHOLATE3ALPHA,7ALPHA-DIHYDROXY-5BETA-CHOLANIC ACIDChenodeoxychoLURSODEOXYCHOLOC ACID3a,7a-Dihydroxy-5b-cholanoic acid(R)-4-((3R,5S,7R,8R,9S,10S,13R,14S,17R)-3,7-dihydroxy-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanoic acid
FluibilChenocolChenossilCholanormXenbilox3alpha,7alpha-Dihydroxy-5beta-cholan-24-oic acidHenoholChenique Acid

Database identifiers

CAS
474-25-9

Properties

Computed structural properties

XLogP
4.9
Topological polar surface area
77.8 Ų
Hydrogen bond donors
3
Hydrogen bond acceptors
4
Rotatable bonds
4
Heavy atoms
28
Formal charge
0
Complexity
605

Experimental & physicochemical properties

Chemical ClassesBile Acids -> Quant Bile Acids
DrugsPharmaceuticals -> Listed in ZINC15
LipidsLipids -> Sterol Lipids [ST] -> Bile acids and derivatives [ST04] -> C24 bile acids, alcohols, and derivatives [ST0401]
LogP4.15
Solubility0.0899 mg/mL
Human Drugs · 4 items

Breast Feeding; Lactation; Milk, Human; Bile Acids and Salts; Cholagogues and Choleretics; Cholic Acids; Gastrointestinal Agents

FDA approved drugs -> Active ingredient

EMA approved medicines: Human medicine (Orphan designations)

FDA approved drugs -> Active ingredient

Melting Point · 2 items

168-171

165 - 167 °C

Physical DescriptionSolid
Collision Cross Section · 6 items

Safety & regulation

Safety information is for reference only and does not replace the supplier’s Safety Data Sheet (SDS), applicable regulations, or professional assessment.

GHS classification

GHS Classification · 5 items

This chemical does not meet GHS hazard criteria for 8.3% (1 of 12) of reports.

Warning

H302 (16.7%): Harmful if swallowed [Warning Acute toxicity, oral]

P203, P261, P264, P264+P265, P270, P271, P280, P301+P317, P302+P352, P304+P340, P305+P351+P338, P317, P318, P319, P321, P330, P332+P317, P337+P317, P362+P364, P403+P233, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 12 reports by companies from 8 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

Hazard information

Regulatory Information · 2 items

Hazard Traits - Developmental Toxicity

REACH registered substance: Chenodeoxycholic acid (EC: 207-481-8)

Other Safety InformationIMAP assessments - Cholan-24-oic acid, 3,7-dihydroxy-, (3.alpha.,5.beta.,7.alpha.)-: Environment tier I assessment
Hazard Classes and CategoriesAcute Tox. 4 (16.7%)

Toxicology

Hepatotoxicity · 1 item

In multiple clinical trials of chenodiol therapy for dissolution of gallstones, serum aminotransferase elevations occurred in up to 30% of patients. The elevations generally arose within 2 months of starting therapy and were typically mild, transient and not accompanied by symptoms or jaundice. Liver biopsies done during chenodiol therapy generally showed mild, nonspecific changes. Clinically apparent liver injury with jaundice was not reported. The liver enzyme elevations were generally dose related and usually did not recur on restarting chenodiol at lower doses. While the serum enzyme abnormalities that occurred on chenodiol therapy generated considerable concern, they appeared to be relatively benign. Since the approval of chenodiol and its more widespread use, at least four instances of liver injury with jaundice have been reported to the sponsor, but the clinical features and outcomes of these cases have not been published. Nevertheless, the product label for chenodiol includes a boxed warning about hepatotoxicity although it does not provide advice on the frequency or how to respond to abnormalities. Thus, the reliability of reports of clinically apparent liver injury with chenodiol therapy remains unclear. Once ursodiol was found to be equally as effective as chenodiol, even at lower doses, and was rarely associated with serum enzyme elevations, it rapidly replaced chenodiol as medical therapy for gallstones.

Chemistry & industry

Pharmacology

ATC Code · 2 items

A - Alimentary tract and metabolism

QA - Alimentary tract and metabolism

PharmacodynamicsIt acts by reducing levels of cholesterol in the bile, helping gallstones that are made predominantly of cholesterol to dissolve. Chenodeoxycholic acid is ineffective with stones of a high calcium or bile acid content.
Mechanism of Action · 1 item

Chenodiol suppresses hepatic synthesis of both cholesterol and cholic acid, gradually replacing the latter and its metabolite, deoxycholic acid in an expanded bile acid pool. These actions contribute to biliary cholesterol desaturation and gradual dissolution of radiolucent cholesterol gallstones in the presence of a gall-bladder visualized by oral cholecystography. Bile acids may also bind the the bile acid receptor (FXR) which regulates the synthesis and transport of bile acids.

Metabolism/Metabolites · 1 item

Chenodiol is well absorbed from the small intestine and taken up by the liver where it is converted to its taurine and glycine conjugates and secreted in bile. At steady-state, an amount of chenodiol near the daily dose escapes to the colon and is converted by bacterial action to lithocholic acid. About 80% of the lithocholate is excreted in the feces; the remainder is absorbed and converted in the liver to its poorly absorbed sulfolithocholyl conjugates. During chenodiol therapy there is only a minor increase in biliary lithocholate, while fecal bile acids are increased three- to fourfold.

FDA Pharmacological Classification · 6 items

0GEI24LG0J

CHENODIOL

Established Pharmacologic Class [EPC] - Bile Acid

Chemical Structure [CS] - Bile Acids and Salts

Chenodiol is a Bile Acid.

CHENODIOL

MeSH Pharmacological Classification · 2 items

Agents that are used to stimulate evacuation of the bowels.

Drugs used for their effects on the gastrointestinal system, as to control gastric acidity, regulate gastrointestinal motility and water flow, and improve digestion.

Related reactions

15 records
New reaction record
HRID 258236 reaction equation
HRID 258236As reactant
HRID 464235 reaction equation
HRID 464235As reactant
HRID 860845 reaction equation
HRID 860845As reactant
HRID 1075740 reaction equation
HRID 1075740As product
HRID 1153703 reaction equation
HRID 1153703As reactant
HRID 1196309 reaction equation
HRID 1196309As reactant
HRID 1659375 reaction equation
HRID 1659375As reactant
HRID 1659376 reaction equation
HRID 1659376As reactant
PreviousPage 1 of 2

Compound notes

On this pageBasic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes
PubChem CID
10133
DTXSID
DTXSID2020260
ChEMBL
CHEMBL240597
ChEBI
CHEBI:16755
UNII
0GEI24LG0J
EC Number
207-481-8
Nikkaji
J2.053B

203.3 Ų [M-H]- [CCS Type: DT; Buffer gas: N2; Ionization: ESI-; Dataset: Bile Acids]

208.5 Ų [M+K-H+HCOO]- [CCS Type: DT; Method: single field calibrated]

195.52 Ų [M+Na]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]

206.57 Ų [M-H]- [CCS Type: DT; Method: stepped-field]

201.51 Ų [M-H]- [CCS Type: DT; Method: single field calibrated with Agilent tune mix (Agilent)]

205.9 Ų [M-H]-

Physicochemical properties

Melting point
165 · 165-167 °C (lit.)
alpha
12 · 12 º (c=1, CHCl3)
Boiling point
437.26 °C · 437.26°C (rough estimate)
Density
0.9985 · 0.9985 (rough estimate)
refractive index
1.446 · 1.4460 (estimate)
Flash point
9 ℃ · 9℃
storage temp.
room temp
solubility
PRACTICALLY INSOLUBLE
pka
4.34 · pKa 4.34 (Uncertain)
form
Powder
color
White to off-white
Water Solubility
PRACTICALLY INSOLUBLE
Merck
13 · 13,2062
BRN
3219887 · 3219887
Major Application
pharmaceutical (small molecule)
InChIKey
RUDATBOHQWOJDD-BSWAIDMHSA-N
SMILES
C[C@H](CCC(O)=O)[C@H]1CC[C@H]2[C@@H]3[C@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C
LogP
3.05 at · 3.05 at 20℃
CAS DataBase Reference
474 · 474-25-9(CAS DataBase Reference)
FDA UNII
0 GEI24LG0J · 0GEI24LG0J
Proposition 65 List
Chenodiol
ATC code
5 AA01 · A05AA01
EPA Substance Registry System
Chenodiol (474-25-9)
UNSPSC Code
41116107 · 41116107
NACRES
25 · NA.25
Symbol(GHS)
7 · GHS07
Signal word
Warning
Hazard statements
315 · H315-H319
Precautionary statements
264 · P264-P280-P302+P352-P305+P351+P338-P332+P313-P337+P313
Hazard Codes
Xn
Risk Statements
63 · 63
Safety Statements
22 · 22-24/25-45-36/37
RIDADR
1230 · UN1230 - class 3 - PG 2 - Methanol, solution
WGK Germany
2 · 2
RTECS
1980000 · FZ1980000
HS Code
29181990 · 29181990
Hazard Classifications
2 Skin · Eye Irrit. 2Skin Irrit. 2
REACH Registrations
Active
Drug Induced Liver Injury · 6 items

Drug Induced Liver Injury Rank (DILIrank 2.0)

Chenodiol

Ambiguous-DILI-concern

8

Warnings & precautions

DOI:10.1016/j.drudis.2016.02.015

Effects During Pregnancy and Lactation◉ Summary of Use during Lactation

Safety data

wgk
2
rtecs
FZ1980000
ridadr
UN1230 - class 3 - PG 2 - Methanol, solution
hs_code
29181990
risk_code
63
Signal word
Warning
Symbol(GHS)
GHS07
hazard_code
Xn
safety_code
22-24/25-45-36/37
Hazard statements
H315-H319
REACH Registrations
Active
Hazard Classifications
Eye Irrit. 2Skin Irrit. 2
Precautionary statements
P264-P280-P302+P352-P305+P351+P338-P332+P313-P337+P313
Absorption, Distribution and Excretion · 2 items

Chenodiol is well absorbed from the small intestine.

About 80% of its bacterial metabolite lithocholate is excreted in the feces.

Tissue LocationsFibroblasts
Cellular LocationsExtracellular
Metabolite Pathways27-Hydroxylase Deficiency
Applications · 8 items

UsesChenodeoxycholic acid is a bile acid synthesized in the liver from cholesterol. henodeoxycholic acid has been used in a study to assess its effects as a long-term replacement therapy for cerebrotendinous xanthomatosis (CTX). It has also been used in a study to investigate its effects on the small-intestinal absorption of bile acids in patients with ileostomies.

DescriptionChenodeoxycholic acid is the first agent to be introduced into the US market for the treatment of radiolucent gallstones. Large scale clinical trials have demonstrated the safety and efficacy of this agent. Chenodeoxycholic acid reduces the biliary concentration of cholesterol relative to that of bile acids and phospholipid, reducing the saturation and thus the lithogenicity of the bile. Success rates in dissolving gallstones are in the range of 50-70% within 4-24 months of treatment. Continuation of the drug after stone dissolution may be required to prevent reoccurrence. Chenodeoxycholic acid is the 7α-isomer of ursodeoxycholic acid which was introduced into the European market in 1978. chenodeoxycholic acid structure

HistoryChenodeoxycholic acid was isolated in 1924 from goose gall by Adolf Windaus and human gall by Heinrich Wieland.Its complete structural configuation was elucidated by Hans Lettre at the University of Gottingen. In 1968, William Admirand and Donald Small at Boston University Medical School established that in patients with gallstones their bile was saturated with cholesterol, sometimes even exhibiting microcrystals, whereas this was not the case in normal people.It was then found that biliary levels of cholic acid and chenodeoxycholic acid were lower in patients with cholesterol gallstones than in normal people. Leslie Thistle and John Schoenfield at the Mayo Clinic in Rochester, Minnesota, then administered individual bile salts by mouth for four months and found that chenodeoxycholic acid reduced the amount of cholesterol in the bile.This led to a national collaborative study in the United States, which confirmed the effectiveness of chenodeoxycholic acid in bringing about dissolution of gallstones in selected patients. However, recent developments such as laparoscopic cholecystectomy and endoscopic biliary techniques have curtailed the role of chenodeoxycholic acid and ursodeoxycholic acid in the treatment of cholelithiasis.

Usesanticholithogenic, antilipemic agent

UsesAn apoptosis inducer via PKC-dependent signalling pathway.

UsesA major bile acid in many vertebrates, occurring as the N-glycine and/or N-taurine conjugate. With other bile acids, forms mixed micelles with lecithin in bile which solubilize cholesterol and thus fa cilitates its excretion. Fcilitates fat absorption in the small intestine by micellar solubilization of fatty acids and monoglycerides. Anticholelithogenic. Epimeric with Ursodiol.

UsesChenodeoxycholic acid is a bile acid that induces apoptosis through protein kinase C signaling pathways.It is a major bile acid in many vertebrates, occurring as the N-glycine and/or N-taurine conjugate. With other bile acids, forms mixed micelles with lecithin in bile which solubilize cholesterol and thus facilitates its excretion.Bile acids are essential for solubilization and transport of dietary lipids, are the major products of cholesterol catabolism, and are physiological ligands for farnesoid X receptor (FXR), a nuclear receptor that regulates genes involved in lipid metabolism.They are also inherently cytotoxic, as physiological imbalance contributes to increased oxidative stress. Bile acid-controlled signaling pathways are promising novel targets to treat such metabolic diseases as obesity, type II diabetes, hyperlipidemia, and atherosclerosis. Chenodeoxycholic acid is widely utilized in therapeutic applications. It is applied in medical therapy to dissolve gallstones. It is employed in the treatment of cerebrotendineous xanthomatosis. It is used to treat constipation and cerebrotendineous xanthomatosis. It acts as a urea receptor in supramolecular chemistry which can contain anions. It is a staining additive commonly used with ruthenium or organic photo-sensitizers in the preparation of staining solutions for dye solar cells. Chenodeoxycholic Acid is a staining additive commonly used with ruthenium or organic photo-sensitizers in the preparation of staining solutions for Dye Solar Cells. This co-adsorbent will prevent dye aggregation on the semiconductor surface, reducing losses in the solar cell's operation. Chenodeoxycholic Acid is a white solid added with the dye powder to the solvent while preparing staining solutions. The concentration of co-adsorbent is typically 10 fold the dye concentration. Chenodeoxycholic acid has been used in a study to assess its effects as a long-term replacement therapy for cerebrotendinous xanthomatosis (CTX). It has also been used in a study to investigate its effects on the small-intestinal absorption of bile acids in patients with ileostomies. Chenodeoxycholic acid (CDCA) is a hydrophobic primary bile acid that activates nuclear receptors involved in cholesterol metabolism.EC50 concentrations for activation of FXR range from 13-34 μM.In cells, CDCA also binds to bile acid binding proteins (BABP) with a reported stoichiometry of 1:2.CDCA toxicity is linked to increased cellular glutathione levels and increased oxidative stress. Exposure of cells to excess CDCA contributes to liver and intestinal cancers.

General DescriptionChenodeoxycholic acid is a bile acid synthesized in the liver from cholesterol.

Upstream & downstream products

Upstream raw materials

Sodium cholateEthanolHydrochloric acid alcoholBarium chlorideSodium carbonateHydrazine hydratePotassium hydroxide

Downstream products

Ursodeoxycholic acidsqualamineChenodeoxycholic acid sodiumTaurochenodeoxycholic acid sodium saltGlycochenodeoxycholic acid sodium salt
Additional notes · 1 item

DefinitionChEBI: Chenodeoxycholic acid is a dihydroxy-5beta-cholanic acid that is (5beta)-cholan-24-oic acid substituted by hydroxy groups at positions 3 and 7 respectively. It has a role as a human metabolite and a mouse metabolite. It is a bile acid, a dihydroxy-5beta-cholanic acid and a C24-steroid. It is a conjugate acid of a chenodeoxycholate.